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Abstract: The way rheumatoid arthritis is treated has changed dramatically with the introduction 
of anti-tumor necrosis factor (anti-TNF) biologics. Nevertheless, many patients still have less 
than adequate control of their disease activity even with these therapeutic regimens, and current 
knowledge fails to explain all the data already gathered. There is now a wide range of drugs 
from different classes of biologic disease-modifying anti-rheumatic drugs available (and soon 
this number will increase significantly), that provides the opportunity to address each patient as 
a particular case and thereby optimize medical intervention. Currently available biologics for 
the treatment of rheumatoid arthritis apart from anti-TNF-based therapies are reviewed, along 
with an analysis of the new insights they provide into the pathogenesis of the disease and a 
discussion of future prospects in the area.
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Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease of adult-
hood. Although both sexes and every age group may be affected, it is more frequent 
in women in the fourth and fifth decades of life. The disease may cause damage to 
various organs and tissues, including the lungs, skin, and heart, but predominantly 
affects the joints. Further, there is a strong association with increased cardiovascular 
risk, which ultimately leads to premature death.1 Arthritis is the most recognized and 
studied manifestation of the disease, being the area in which the most extensive data 
have been gathered from a pathophysiologic point of view, and the one that is evalu-
ated in the large majority of clinical trials.
The way RA is treated has changed dramatically in the last 15 years with the 
introduction of biologics, namely anti-tumor necrosis factor (TNF) therapy. With the 
use of these molecular targeted therapies, the standard of care for patients with RA 
has improved, better clinical results have been achieved, and knowledge about the 
pathogenesis of RA has grown exponentially. Nevertheless, many patients still have less 
than adequate control of their disease activity even with these therapeutic regimens or 
become resistant to their beneficial effects. This imposes the need for other treatment 
options, and suggests that current theories about RA may be only partially correct. 
In recent years, other drugs have been produced that target other components of the 
inflammatory process in RA, with good efficacy and safety profiles, which eventu-
ally led to their approval and widespread use. It is the aim of this paper to review 
the biologics currently available for the treatment of RA apart from anti-TNF-based 
Biologics: Targets and Therapy 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Paula and Alves
therapies, to analyze the new insights they provide into the 
pathogenesis of the disease, and to discuss future prospects 
in the area.
Etiology and pathogenesis
A clear etiology for RA has never been identified. Genetic 
factors clearly play a role, as revealed by an up to 30% con-
cordance rate in monozygotic twins,2,3 and most genomic 
association studies point to the major histocompatibility 
complex locus as the one with the highest relative risk.4 The 
most important environmental risk factor is smoking, and 
some microbes (such as Porphyromonas gingivalis infection 
in periodontal tissue) have been implicated, but this has been 
regarded as of uncertain value.5
RA is characterized by activation of resident synovial 
inflammatory cells, mainly macrophages, infiltration of lym-
phocytes and neutrophils in the synovium, and the production 
of an inflammatory milieu, which in turn promotes prolifera-
tion of synoviocytes and fibroblasts, and neoangiogenesis. The 
presence of autoantibodies (rheumatoid factor and anti-cyclic 
citrullinated peptide antibodies), a reflection of the role of 
B-cells, is one of the laboratory hallmarks of RA, in some cases 
being detected more than 10 years before clinical onset.6 All this 
leads to an aberrant, hyperplastic architecture of the synovial 
membrane, the rheumatoid pannus, and to the  differentiation 
and activation of osteoclasts and subsequent bone destruction. 
Chondrocyte function is also altered, leading to degradation of 
cartilage and biomechanical derangement of normal articular 
function. Periarticular structures such as ligaments and tendons 
are also eventually involved in the inflammatory process, cul-
minating in further dysfunction and production of the typical 
clinical and radiologic picture of RA.
As such, apart from macrophages and other “effector” 
cell types (dendritic cells, neutrophils, synoviocytes, osteo-
blasts, osteoclasts, and chondrocytes), three components of 
RA pathogenesis have become recognized as major players 
based on both basic and clinical research, ie, B-cells, T-cells, 
and a wide range of inflammatory cytokines and growth 
factors that, acting as an intricate and redundant network 
both systemically and locally, shift the balance towards a 
proinflammatory state. Accumulating evidence shows that 
all these players act interdependently, and have continuously 
challenged our understanding of immune physiology and 
pathology.
After TNF blockers were introduced in the clinical man-
agement of RA, two types of clinical picture have emerged 
in daily practice, ie, an inadequate response and/or existence 
of contraindications or intolerance, precluding the use of 
these agents and raising the need to find alternatives. In fact, 
anti-TNF therapy achieves a 20% improvement in  American 
College of Rheumatology response criteria (ACR20) in about 
42%–85% of patients, and an ACR50 response in only 
21%–69%,7,8 with secondary failure rates of up to 50% dur-
ing the first year.9
Current molecular targeted strategies to control RA 
(beyond TNF) have tried to block at least one of the three 
components mentioned, and the most relevant of those are 
reviewed here.
B-cell-targeted therapies
Role of B-cells in RA
Improvement in RA through B-cell depletion has high-
lighted the importance of B-cells in the pathogenesis of 
the disease. The presence of rheumatoid factor is related to 
disease severity and the frequency of extra-articular mani-
festations,10 and anti-cyclic citrullinated peptide antibodies 
are related to aggressiveness of the disease.11 Moreover, 
baseline rheumatoid factor seropositivity seems to be related 
to the response to rituximab.12–14 However, CD20 is lacking 
in antibody-producing plasmablasts and plasma cells; the 
response to rituximab is related to the level of B-cell depletion 
in peripheral blood15,16 and synovial tissue,17 and is coincident 
with a reduction in the number of peripheral memory B-cells 
(CD19+/CD27+),18 and not with the degree of reduction in 
plasma immunoglobulins.19 Further, relapse is also related to 
B-cell repopulation,20,21 and non-antibody-producing B-cells 
are able to activate T-cells and produce articular disease.22 
All this reinforces the idea of an important role of B-cells 
beyond antibody production.
B-cells are potent antigen-presenting cells22 in the 
context of multiple diseases.23,24 They are able to activate 
CD4+ T-cells, and their presence is necessary for T-cell 
activation in synovial tissue.25 B-cells are also capable of 
enhancing the differentiation of T-cells into the  inflammatory 
T-helper (Th)17 phenotype.26 Further, B-cells are potent 
cytokine producers that act not only in an autocrine manner 
(interleukin [IL]-10) but also activate other immune cells, 
including macrophages, neutrophils, and dendritic cells (IL-6, 
TNF-α, IL-1, and IL-10).27 They are also important sources 
of potent chemotactic molecules that are crucial to pannus 
development.28,29 These findings add a twist to the classical 
view of T-helper cells ensuring activation and maturation of 
B-cells and innate immunity activating adaptive immunity. 
They also suggest that the presence of autoantibodies may be 
interpreted in RA as a manifestation of loss of tolerance and 
of the presence of autoreactive B-cells that are themselves 
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pathogenic, even before differentiating into permanent 
antibody-producing plasma cells.
The case for rituximab
Blocking the contribution of B-cells to disease activity 
has been achieved by B-cell-depleting therapies with great 
 success. Rituximab, a chimeric monoclonal anti-CD20 
 antibody originally used in non-Hodgkin’s lymphoma, 
induces antibody-dependent cell-mediated cytotoxicity, 
complement-dependent cytotoxicity, and apoptosis of B-cells 
in various stages of development,27,30,31 leading to their 
transient but almost complete depletion in peripheral blood, 
although only partially in the bone marrow and synovial 
tissue niches.32,33
The beneficial effect of rituximab-induced B-cell deple-
tion has been substantiated in various major randomized 
clinical trials in RA, as well as in other immune-mediated 
diseases.34 The benefit is reflected in a reduction of clinical 
disease activity and laboratory inflammation markers, halted 
radiographic progression, and better functional ability and 
quality of life scores. The effect consistently lasts for more 
than 6 months after a single course of two administrations 
of the drug, separated by 15 days, with clear benefit when 
compared with placebo, and with a good safety profile. This 
has been observed in methotrexate-naïve patients (anti-TNF-
naïve) in IMAGE (International Study in Methotrexate-
naïve Subjects Investigating Rituximab’s Efficacy),13 and in 
methotrexate-inadequate responders in SERENE40 (Study 
 Evaluating Rituximab’s Efficacy in MTX iNadequate 
rEsponders) and MIRROR35 (Methotrexate Inadequate 
Responders Randomized study Of Rituximab), with com-
parable results. In SERENE,40 ACR20, ACR50, and ACR70 
responses at 24 weeks were 51%, 26%, and 10%, respectively, 
with a clear-cut difference from placebo (23%, 9%, and 
5%). Importantly, in REFLEX36 (Randomized Evaluation 
oF Long-term Efficacy of rituXimab in RA), rituximab again 
produced similar results in anti-TNF-inadequate responders, 
with ACR20, ACR50, and ACR70 responses at 24 weeks of 
51%, 27%, and 12%, respectively. A benefit from placebo has 
been shown for up to 5 years of continued rituximab retreat-
ment in a post hoc open-label extension of REFLEX.37 The 
MIRAR trial focused on an important issue directly comparing 
the use of an alternative anti-TNF versus rituximab after a 
first anti-TNF failure, with both treatments producing com-
parable benefits.38 Conversely, several observational studies 
have suggested that rituximab may be more effective than a 
second anti-TNF in some subgroups,39 although clinical trials 
confirming this are lacking.
Rituximab has shown to be effective in monotherapy, but 
considerably less so when used in combination with metho-
trexate, both in the magnitude and duration of benefit.12,40 
This is one of the major caveats of using rituximab in RA 
because tocilizumab is still preferred as an alternative to 
anti-TNF agents for methotrexate-intolerant patients or when 
methotrexate is contraindicated, such as in severe pulmonary 
disease. The use of rituximab with other synthetic disease-
modifying antirheumatic drugs (DMARDs), mainly lefluno-
mide, has been evaluated as producing similar results,41 but 
large  head-to-head randomized trials are still lacking.
In light of these accumulated data, there seems to be 
no reason for rituximab not being recommended as a first-
line agent. However, rituximab’s debut in the treatment of 
RA was somewhat obscured by the initial enthusiasm for 
anti-TNF agents, and its initial use in malignancies may 
have raised some concern regarding its widespread use. In 
Europe, rituximab was approved in RA patients with severe 
disease, but only after failure of at least one anti-TNF agent 
(and always in association with methotrexate).42 However, in 
the more recent 2012 ACR guidelines, rituximab has already 
been recommended as a first-line biologic agent after syn-
thetic DMARD failure for patients with moderate to severe 
disease activity and for those with low disease activity and 
poor prognosis markers.43
Some controversy still exists regarding the optimal dosage 
of rituximab. The evidence suggests that a 2 × 500 mg regimen 
has almost similar efficacy to the 2 × 1 g regimen used in the 
majority of trials, with a reduced rate of infusion reactions 
and adverse events.44 However, the full-dose regimen seems to 
result in better ACR70 response rates, and better radiographic 
outcomes were produced in the IMAGE trial.13 As such, the 
approved dose in most consensus guidelines is 2 × 1 g.
Beyond rituximab
CD20 is absent in long-lived plasma cells and plasmablasts 
and is not expressed until after the pre-B stage of B-cell 
development. As such, rituximab therapy is not expected to 
interfere directly with permanent antibody- producing cells, 
but rather with their precursors. Also, the bone marrow con-
sists of a protective niche, being largely refractory to B-cell 
depletion after administration of rituximab.32,33,45 Importantly, 
synovial tissue seems to be also relatively resistant to the 
action of rituximab.32,33 In RA, the synovial tissue is infiltrated 
with B-cells and T-cells,  producing three types of synovitis: 
diffuse synovitis, in which both types of cells are interspersed 
with no apparent spatial organization; follicular synovitis, 
in which ectopic germinal centers form, with a nucleus of 
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B-cells  surrounded by T-cells and with autoantibody-secreting 
capacity;46 and granulomatous synovitis. Sex, age, disease 
duration, and previous treatment do not correlate with the type 
of synovitis found, and each patient shows only one type. This 
suggests that there may be different subtypes of the disease. 
Accordingly, seronegative RA patients tend to have a diffuse 
pattern, and all patients with follicular synovitis were seroposi-
tive in a cohort of 21 cases.47 Additionally, rheumatoid nod-
ules, a common extra-articular manifestation of the disease, 
seem to be closely associated with granulomatous synovitis. 
Interestingly, rheumatoid factor levels tend to be higher and 
the effect of rituximab on immunoglobulin levels in synovial 
fluid tends to be more pronounced in follicular synovitis.32 In 
one study, the diameter of follicular aggregates was signifi-
cantly associated with disease severity,48 but no comparison 
was made between the different types of synovitis. The clinical 
efficacy of rituximab or even baseline disease activity in each 
subgroup was never evaluated. Nevertheless, these studies 
show that B-cells in local synovial tissue are crucial deter-
minants of the disease, and a more potent way of inhibiting 
B-cell function in the synovium could be interesting.
CD19, a membrane-associated molecule involved in 
modulation of the threshold of B-cell activation, is present 
in a larger range of B-cells, including plasmablasts, plasma 
cells, and pre-B cells,49 and is also specific for B-cells. In 
contrast with rituximab, administration of anti-CD19 mono-
clonal antibody depletes the majority of B-cells in the bone 
marrow, lymphoid organs, and synovial tissue,50 as well as 
some anti-CD20-resistant subtypes resident in the peritoneal 
cavity (B1a, B1b),50,51 potentially leading to an increased 
clinical efficacy, as was observed in animal models of RA. 
There is, however, some concern that depletion of regulating 
B10 (CD20-) cells could induce autoimmunity.52 Depletion 
of plasma cells also induces at least a partial loss of protec-
tive immunity, which could lead to increased safety issues 
concerning the risk of infection. These issues have not been 
fully addressed in humans, with the only experience having 
been gathered in patients with hematologic malignancies, first 
with a mouse anti-hCD19,53 then with a humanized version,54 
with both having shown an acceptable safety profile.
Other strategies to block the B-cell contribution to RA 
have been envisaged, including blocking B-cell activation with 
an anti-BAFF/BLyS (B-cell activating factor/B- lymphocyte 
stimulator) antibody (belimumab)55 or with a TACI-immuno-
globulin fusion protein (atacicept) which blocks both BLyS 
and APRIL (A PRoliferation  Inducing Ligand) costimula-
tors.56 Belimumab has shown modest efficacy (only ACR20 
responses different from placebo), although with a good 
safety profile, mainly in moderate to severe, seropositive, 
anti-TNF-naïve RA patients who have failed methotrexate 
therapy.57 Atacicept did not meet expectations, producing no 
clinical improvement, but is safe to use in methotrexate-inad-
equate responders58 or after antiTNF failure.56 It is interesting 
to note that atacicept fulfilled its expected biological effect,59 
reducing circulating immunoglobulin levels and autoantibody 
titers,58 which reinforces the notion of autoantibodies being 
markers of disease and not effectors per se.
T-cell-targeted therapies
Role of T-cells in RA
T-cells are found within the synovial tissue in RA, and play 
a major role in perpetuating inflammation and producing tis-
sue damage. They are activated by antigen-presenting cells, 
including dendritic cells, macrophages, and even B-cells, 
and subsequently secrete various cytokines (which contribute 
to inflammation in synovial tissue), activate innate immune 
cells, support B-cell activation, and induce destructive 
chondrocyte and osteoclast activation. Various subtypes of 
T-helper cells have been described, and modulation of the dif-
ferentiation of naïve T-cells into each of those types is being 
increasingly studied, and proving to be central in RA.
The inflammatory pattern in RA has long been charac-
terized by a shift towards a Th1 phenotype in CD4+ T-cell 
differentiation. This leads to a predominant production of 
Th1-associated cytokines such as interferon-gamma, with 
Th2-associated cytokines such as IL-4 and IL-13 found to 
be nearly absent in the synovial tissue.60 The Th17 subtype of 
CD4+ T-cells is today recognized as a major player in synovial 
inflammation and bone erosion, mainly by the production 
of IL-17 and IL-23.61 In fact, the pivotal role of Th1 in the 
pathogenesis of RA has been increasingly recognized as taking 
place via actions ascribed to Th17, and it is not clear whether 
Th17 cells consist of a specialized Th1 subtype or a different 
phenotype that would act in concert with Th1 cells. Th17 
differentiation from naïve T-cells seems to require IL-6 and 
transforming growth factor-beta concomitant signaling, and 
their proliferation is dependent on IL-23, produced by antigen-
presenting cells.62,63 In any case, both subtypes seem to have 
an important role in the regulation of inflammation in RA. The 
relative weight of each one is still under discussion.
Conversely, inhibition of regulatory T-cell (Treg) dif-
ferentiation seems to be important in the perpetuation of 
autoimmune diseases,64 and their numbers and activation 
status are associated with RA activity in general65,66 and with 
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the response to treatment with either synthetic or biologic 
DMARDs.67,68
Case for abatacept
Efforts to block T-cell activity in RA have produced important 
results.69 Abatacept, a human CTLA4-IgFc (CTLA, cytotoxic 
T-lymphocyte antigen) fusion protein, binds to CD80/86 
on antigen-presenting cells and competitively prevents its 
binding to the T-cell CD28 molecule (CTLA). CD80/CD86-
CD28 interaction produces a crucial costimulatory signal 
upon major histocompatibility complex-T-cell receptor 
interaction, and its blocking inhibits T-cell activation. Admin-
istration of abatacept subsequently leads to impaired B-cell 
activation and reduced levels of autoantibodies, together 
with a reduction in T-cell-mediated activation of osteoclasts 
and diminished cytokine release from T-cells, B-cells, and 
macrophages.70,71 This translates into reduced disease activity, 
a decrease in inflammatory markers and halted bone erosion, 
as seen in various randomized clinical trials supporting its 
use, with benefits being present as early as 1–4 months of 
continued administration.72 Abatacept is more effective in 
anticyclic citrullinated peptide antibody-positive patients.73 
The reason for this is unknown, and emphasizes that RA is 
a syndrome with multiple subtypes that may respond differ-
ently to different therapies.
The efficacy and safety of abatacept was consistently 
shown in biologic-naïve methotrexate-inadequate responders 
in the AIM (Abatacept in Inadequate responders to Metho-
trexate) trial,74 with ACR20, ACR50, and ACR70 responses 
of 68%, 40%, and 20%, respectively, compared with 40%, 
17%, and 6.5% with placebo, at 24 weeks. In the same group 
of patients, abatacept produced similar results as a first-line 
biologic agent when compared with the anti-TNF agent inflix-
imab in ATTEST (Abatacept or infliximab versus placebo, a 
Trial for Tolerability, Efficacy and Safety in Treating RA).75 In 
this trial, it was even suggested that abatacept could be more 
effective than infliximab in sustaining clinical improvement 
and remission rates after 12 months of therapy.
Abatacept also proved to be an effective therapeutic 
option after failure of an anti-TNF agent in ATTAIN (Abata-
cept Trial in Treatment of Anti-TNF INadequate responders)76 
(ACR20, ACR50, and ACR70 responses of 50%, 20%, and 
10%, respectively, versus 19%, 4%, and 1% in controls), 
and also in the open-label extension of the ATTEST trial, 
with infliximab-inadequate responders being rescued by 
abatacept.77 Additionally, no washout period is necessary 
before abatacept treatment after anti-TNF failure.78
Because clinical guidelines increasingly value the 
 recognition of poor prognostic markers to justify the immedi-
ate beginning of biologic DMARDs, abatacept also produced 
a good clinical and radiographic response in methotrexate-
naïve patients with early erosive RA in AGREE (Abatacept 
trial to Gauge Remission and joint damage progression in 
methotrexate-naïve patients with Early Erosive rheumatoid 
arthritis).79
Administration of abatacept in the majority of clinical 
trials refers to the 20 mg/kg monthly intravenous regimen, on 
background methotrexate. It has become increasingly clear 
that subcutaneous administration is equally effective and 
safe.80 Subcutaneous injection requires a much smaller dose 
(125 mg weekly injections, 500 mg per month), which has a 
clear advantage when considering cost-effectiveness.
Abatacept monotherapy (without methotrexate) has not 
been sufficiently studied. In the ACCOMPANY (Abata-
cept in Subjects with Rheumatoid Arthritis Administered 
Plus or Minus Background Methotrexate Subcutaneously) 
trial, subcutaneous abatacept showed similar efficacy and 
immunogenicity whether with or without methotrexate.81 
Data regarding combination regimens with other synthetic 
DMARDs are sparse.
Abatacept is presently included in clinical consensus and 
guidelines in Europe as an option after anti-TNF failure, 
always in combination with methotrexate.42 In Switzerland, 
it has already been adopted as a first-line biologic agent, in 
concordance with the results referred to above.72 In the US, 
like rituximab, it has also been included in the recommenda-
tion guidelines43 as a first-line biologic agent for all patients 
with moderate to severe disease activity and for patients with 
low activity and poor prognostic markers who have failed 
synthetic DMARDs.
Beyond abatacept
Abatacept, as a costimulation blocker, inhibits the activation 
and proliferation of all T-cell subtypes,82 including Tregs. 
This is in contrast with the mechanism of action of other 
biologic agents such as anti-IL-6R, anti-CD20, or anti-TNF, 
which enhance Treg regulatory function, thereby ameliorating 
disease. Maintaining Treg function by selectively inhibiting 
other T-cell subtypes would imply a different molecular tar-
get, as CTLA-IgFc is nonspecific. More precise modulation 
of the T-cell activation pattern, selectively inhibiting Th1 and 
Th17 subtypes, would theoretically result in a more effective 
way of controlling disease activity, maybe even with fewer 
adverse effects with respect to susceptibility to infection.
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Combination therapy with other biologics has been tried. 
Association with an anti-TNF agent (etanercept) did not pro-
duce significant clinical benefits, but induced a serious rise 
in adverse event rates.83 Combination regimens with other 
biologics such as tocilizumab remain to be tested.
Anti-cytokine agents
Targeting specific cytokines involved in the inflammation 
process in the joints and systemically has been a logical 
strategy for controlling disease activity.84 It modulates not 
only the direct effects of these cytokines on critical “effec-
tor” cells such as osteoclasts, chondrocytes, or macrophages, 
but also has indirect cell-mediated effects subsequent to the 
differential pattern of activation and differentiation of T-cells 
and B-cells.85 Anti-TNF agents were the first successful case, 
leading to the most impressive improvement in the care of 
patients with RA. Targeting IL-6 signaling was the next 
successful step, leading to widespread use of the anti-IL-6 
agent tocilizumab. In the future, drugs inhibiting the signal-
ing of other cytokines such as IL-12, IL-13, and IL-17 may 
be promising strategies in the treatment of RA.
IL-6 in RA
IL-6 is produced by several cell types, including dendritic 
cells, B-cells, macrophages, and endothelial cells, upon 
their induction by inflammatory stimuli such as TNF-α, 
and is present in large quantities in the synovial fluid of 
RA-affected joints and in serum. It has a central role in the 
pathogenesis of RA, inducing endothelial activation, neutro-
phil activation and chemotaxis, directly activating osteoclasts 
and chondrocytes and stimulating matrix turnover and bone 
erosion.86 IL-6 is also responsible for important biases in 
T-cell development.62 Through inhibition of interferon-
gamma and enhancing IL-4 signaling, IL-6 produces a shift 
towards a Th2 phenotype of CD4+ T-cells, which is in contrast 
with the main Th1 response seen in RA. An explanation for 
this contradiction may come from the discovery that IL-6 is 
central to the Th17 differentiation of naïve T-cells when in the 
presence of transforming growth factor-beta.62 Th17 T-cells 
are known to be potent inflammatory cells in the synovium, 
mainly through the production of IL-17, which inhibits Th2 
differentiation in favor of the Th1 phenotype; this could 
explain the contradictory isolated actions of IL-6, which also 
inhibits Treg differentiation, contributing to inflammation 
and loss of tolerance.
Further, IL-6 is largely responsible for the systemic effects 
of RA.87 By inducing the expression of hepcidin, IL-6 con-
tributes to the inflammatory anemia seen in many patients. 
Fatigue in RA is closely correlated with IL-6  concentrations 
in serum. IL-6 induces the production of acute-phase 
 reactants in hepatocytes via the JAK/STAT signaling pathway, 
including C-reactive protein and serum amyloid A. C-reactive 
protein binds to apolipoprotein B-containing lipoproteins88 
and increases the uptake of low-density lipoprotein in ather-
omatous lesions.89 Serum amyloid A, in turn, was shown 
to be introduced into cholesterol-containing high-density 
lipoprotein particles, impairing protective reverse cholesterol 
transport90,91 and inducing formation of foam cells.92
The case for tocilizumab
Blocking IL-6 signaling by administration of tocilizumab 
has produced consistent results whether in combination with 
methotrexate or in monotherapy.93 In OPTION94 (Tocilizumab 
Pivotal Trial in Methotrexate Inadequate RespONders), the 
superiority of tocilizumab with methotrexate was shown in 
methotrexate-inadequate responders, when compared with 
methotrexate alone, for both clinical response and inflamma-
tory markers (ACR20, ACR50, and ACR70 responses of 59%, 
44%, and 22%, respectively, at 24 weeks versus 26%, 22%, 
and 4% with placebo). The LITHE (Tocilizumab Safety and 
the Prevention of Structural Joint Damage)95 study  confirmed 
a benefit in radiographic outcomes for tocilizumab. In the 
TOWARD96 (Tocilizumab in Combination With  Traditional 
DMARD Therapy) trial, a significant response was also seen 
when in combination with any synthetic DMARD versus 
any DMARD in monotherapy in patients with an inadequate 
response to synthetic DMARD therapy. After failure of one 
anti-TNF agent, tocilizumab also proved to be beneficial in 
combination with methotrexate (ACR20, ACR50, and ACR70 
responses of 50%, 29%, and 12% at 24 weeks versus 10%, 
3.8%, and 1.3% with methotrexate only) in the RADIATE97 
(Research on Tocilizumab Determining Efficacy after Anti-
TNF Failures) trial.
The efficacy of tocilizumab in monotherapy has been 
increasingly substantiated. In the ACT-RAY98 (Adding tocili-
zumab or switching to tocilizumab monotherapy in metho-
trexate inadequate responders: 24-week symptomatic and 
structural results of a 2-year randomised controlled strategy 
trial in rheumatoid arthritis) study, addition of methotrexate to 
tocilizumab therapy in methotrexate-inadequate responders 
brought no benefit, and the AMBITION99 (Comparison of 
tocilizumab monotherapy versus methotrexate monotherapy 
in patients with moderate to severe rheumatoid arthritis) trial 
showed clear superiority of tocilizumab in monotherapy ver-
sus methotrexate alone as soon as 6 months in patients naïve 
to any biologic or methotrexate. These data make tocilizumab 
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an excellent choice (if not the only one) in the large group 
of patients who are intolerant or have contraindications to 
methotrexate (about 30%).100
An important advantage of tocilizumab is its ability to 
control the extra-articular manifestations of RA, namely 
chronic inflammatory anemia, asthenia, and cardiovascular 
risk. Tocilizumab was seen to raise hemoglobin levels and 
to alleviate asthenia.87 Initially, the impact of tocilizumab 
on the lipid profile, ie, increasing total cholesterol levels, 
raised concern that it could increase cardiovascular risk. 
However, total cholesterol levels are increased at the expense 
of both low-density and high-density lipoprotein particles, 
in a ratio that may actually confer a protective effect on 
 atherogenesis.101 This, in parallel with the benefit conferred 
by reducing atherogenic acute-phase proteins (see above), 
suggests that tocilizumab may be an excellent drug for pre-
venting cardiovascular comorbidity in these patients.
In Europe, tocilizumab is recommended in the 2010 
European League Against Rheumatism guidelines only after 
failure of at least one anti-TNF agent, with or without a 
synthetic DMARD.42 In the US, tocilizumab is suggested in 
the 2012 ACR guidelines as an option only after failure of an 
anti-TNF, abatacept or rituximab,43 although it was approved 
by the US Food and Drug Administration for moderate to 
severe RA with inadequate response to any DMARD. Also, 
in the US the initial recommended dose of tocilizumab is 
4 mg/kg while in Europe it is 8 mg/kg. In the large majority 
of clinical trials, tocilizumab was tested with the 8 mg/kg 
dose, making this regimen the one most supported by the 
available evidence. Nevertheless, there have been some 
reports and registry data supporting the use of the 4 mg/kg 
dose, especially when there are concerns about toxicity and 
the patient has achieved remission.102
Beyond tocilizumab
IL-6 signaling has an important singularity: the membrane-
bound IL-6 receptor is a hexameric complex composed of 
a nonsignaling IL-6 binding molecule and two signaling 
molecules called gp130 (shared by all members of the IL-6 
family of receptors).63 Many cell types, upon IL-6 signaling or 
during apoptosis, shed cleaved soluble molecules of the IL-6 
receptor (IL-6R). This soluble version of IL-6R may thereby 
interact with membrane-bound gp130 in cell types which do 
not normally express the IL-6R molecule, conferring on them 
the capacity to be responsive to IL-6 signaling. This process, 
called trans-signaling,103 is responsible for a fair amount of 
the recognized actions of IL-6 including its systemic effects, 
T-cell induction, and chemotaxis. In animal models,  blockade 
of IL-6 trans-signaling with a gp130-Fc fusion protein 
 produced interesting results, alleviating arthritis104 and even 
reducing atherogenesis. Most importantly, it did better than 
IL-6R blockade in a sepsis model, conferring 100% survival 
after cecal puncture.105 The use of trans-signaling-selective 
blocking agents has not yet been tested in humans, but they 
could serve as a valid strategy to maintain the major efficacy 
of tocilizumab with much less toxicity and fewer side effects. 
Human trials are programmed for 2013, and the results are 
awaited with some enthusiasm.
On the other hand, inhibition of one of the major intracel-
lular effectors of IL-6 signaling, ie, the JAK-STAT pathway, 
has been given much attention, and preliminary results are 
being received with enthusiasm. JAK and STAT molecules 
have several isoforms which are expressed differently in 
multiple cell types. They are intracellular messengers for a 
multitude of kinase cell receptors, including erythropoietin, 
interferon-gamma, IL-4, and IL-23, apart from IL-6.106 Given 
its pleiotropic use throughout development, maintenance and 
regeneration of adult tissue, overt blocking of JAK-STAT 
 signaling would be necessarily fatal, or at least related to 
serious adverse effects. However, selective inhibition of spe-
cific isotypes of JAK or STAT could have a different profile. 
Inhibition of JAK3 by tofacitinib seems to be almost selective 
to lymphocytes, reducing its toxicity, and has a major impact 
on several IL-6 actions (including systemic and cardiovascular 
effects), inhibiting Th1 and Th17 differentiation and enhancing 
Treg expansion.107 Phase III trials have already been conducted 
with an orally available formulation of tofacitinib, which has 
proved to be successful in reducing clinical and laboratory 
disease activity and radiographic progression compared with 
placebo, with a good safety profile. This has been shown at 
least in methotrexate-inadequate responders (ORAL Scan,108 
ORAL Solo,109 and ORAL Standard studies)110 and in other 
DMARD-inadequate responders (ORAL Sync study),111 and 
tofacitinib has shown an efficacy and safety profile similar to 
that of adalimumab, an anti-TNF agent, in association with 
methotrexate, in the ORAL Standard study. In the ORAL Solo 
trial, it even demonstrated effectiveness in reaching clinical 
endpoints in monotherapy.
The forgotten case of anakinra
The IL-1 inhibitor anakinra is a recombinant nonglycosylated 
form of the human IL-1 receptor antagonist. It has proven to 
be superior to placebo in RA patients with moderate to severe 
disease activity in three randomized clinical trials,112–114 
with differences of up to 42% versus 23% on ACR20 
responses (although more modest in ACR50 responses). 
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However, no head-to-head studies have been performed 
comparing anakinra with other biologics. In a meta-analysis 
by Thaler et al,115 anakinra seemed to confer no clinical ben-
efit over anti-TNF therapy, and had a worse safety profile, 
with a greater incidence of infusion reactions (adverse events 
in 67.2% with anakinra versus 17.5%–22.4% with an anti-
TNF). Nevertheless, the data on anakinra are sparse, and for 
that reason it was not included in the 2012 ACR guidelines 
for treatment of RA. It is plausible that anakinra could be 
of interest in specific populations, namely after failure of 
other biologics, but no studies addressing this have been 
published.
Conclusion
A fair amount of exciting information has been gathered over 
the past two decades about the treatment of RA. New bio-
logic agents approved after anti-TNF therapy (Table 1) have 
continued to improve the prognosis, quality of life, and life 
expectancy of RA patients, and a huge number of new agents 
are being tested in Phase II and III clinical trials, whether 
targeting new molecules (eg, sarilumab, a monoclonal anti-
body directed against the alpha subunit of IL-6 receptor, 
or secukinumab, an anti-IL-17 monoclonal antibody)116 or 
improving existing drugs (such as ocrelizumab, a humanized 
version of rituximab).117,118
Even though great efforts are being undertaken to deepen 
our understanding of the pathobiology of RA, controversy 
still exists, and current knowledge fails to explain all the data 
already gathered. RA is clearly a disease with many subenti-
ties, with different outcomes and different potential “optimal 
therapies”. Synovial tissue histology is a good example, 
as each different histopathology pattern is correlated with 
particular treatment responses and clinical characteristics. 
Subgroup-based studies in RA are still in their infancy, but 
could provide a means to identify variables predictive of a 
good biologic treatment response in particular patients.
The outcomes measured in the large majority of clinical 
trials, and even in basic research, are hitherto centered on 
arthritis and quality of life scores. Not taking into account 
all the frequent extra-articular manifestations of RA under-
estimates the systemic burden of disease, and therefore, it is 
possible that the results of these trials could be different if 
a more holistic approach for outcome evaluation had been 
used. Further, disease activity and bone damage seem to be 
unlinked during biologic therapy (at least with rituximab119 
and tocilizumab120), and this may make the use of current dis-
ease activity scores to evaluate the efficacy of such biologic 
therapies even less adequate. On the other hand, some extra-
articular manifestations are often major variables in clinical 
decision-making (eg, pulmonary disease), and thus should 
be more extensively studied and considered; present data 
and guidelines are based on the belief that whatever action 
improves articular disease will improve other manifestations, 
which is not necessarily true. Cardiovascular risk, being the 
major cause of death in this context, has come to attention 
recently, but the impact of each biologic therapy in relation 
to others is still understudied.
There is now a wide range of different drugs from dif-
ferent classes of biologic DMARDs available (and soon this 
number will increase significantly), providing the opportu-
nity to address each patient as a particular case and thereby 
optimize medical intervention. A strong knowledge of the 
Table 1 Currently approved molecular targeted strategies to control RA disease activity
Target Dose/administration ACR50 response  
in MTX-inadequate  
responders at 24 weeks
Main adverse effects
Rituximab CD-20 (B-cells) 2 × 1000 mg-1 g iv 15 days  
apart, single course, repeated  
as soon as after 6 months  
if necessary
26% (SeReNe),40 up to 33%  
in seropositive patients
infusion reactions, 
hepatitis B reactivation, 
progressive multifocal 
leukoencephalopathy
Abatacept CD80/86 on APCs  
(T-cell activation)
3 × 10 mg/kg iv 15 days  
apart, then every month 
125 mg SC once weekly
40% (AiM)74 infections
Tocilizumab iL-6R 4–8 mg/kg iv every 4 weeks 44% (OPTiON)94  
monotherapy
infusion reactions, 
hepatotoxicity, infections, 
neutropenia
Anakinra iL-1R 100 mg SC once daily (can be  
reduced to every other day)
17% (Phase iii trial114) infusion reactions
Abbreviations: RA, Rheumatoid arthritis; APCs, antigen-presenting cells; iL-6R, interleukin-6 receptor; iL-1R, interleukin-1 receptor; MTX, methotrexate; iv, intravenously; 
SC, subcutaneously; ACR50, 50% improvement in American College of Rheumatology response criteria; AiM, Abatacept in inadequate responders to Methotrexate; 
OPTION, Tocilizumab Pivotal Trial in Methotrexate Inadequate RespONders; SERENE, Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders.
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pharmacologic characteristics of all the drugs, together with 
a comprehensive approach to each patient, will allow a true 
informed choice of the best treatment for each case and better 
overall population-based control of the disease.
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